Eikon Therapeutics (EIKN): which funds own it
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Sections with a free account
3 concentrated managers hold it (+1 vs last quarter) with a median weight of 0.0%.
Who owns Eikon Therapeutics?
Holders reporting more than 5% of the shares to the SEC (Schedules 13D/13G): FMR, 10.2% (13G/A filed Oct 7, 2026), James B. Tananbaum, 7.7% (13G filed Feb 11, 2026), BlackRock Portfolio Management, 5.5% (13G filed Apr 29, 2026), Perlmutter Roger M, 5.2% (13G filed May 13, 2026) and Innovation Endeavors III, 5.0% (13G filed May 15, 2026). Kutzkey Tim, Column Group Opportunity III, LP and Foresite Capital Opportunity Management V, LLC are listed on their Form 4 filings as owners of more than 10%. As of Jun 30, 2026, the largest holders reported on Form 13F were FMR (9.2% of the shares), BlackRock (7.9%) and Foresite Capital Management IV (3.6%).
Which institutions hold the most Eikon Therapeutics shares?
Per Form 13F filings as of Jun 30, 2026, as a share of all shares outstanding:
- 1. FMR: 9.2%
- 2. BlackRock: 7.9%
- 3. Foresite Capital Management IV: 3.6%
- 4. Merck: 3.1%
- 5. T. Rowe Price Investment Management: 2.9%
- 6. Foresite Capital Management V: 2.4%
- 7. Capital World Investors: 2.2%
- 8. Price T Rowe Associates: 1.9%
- 9. Vanguard Capital Management: 1.7%
- 10. EcoR1 Capital: 1.4%
How much of Eikon Therapeutics do institutions own?
The 77 institutions that file 13F reported 48.9% of the shares as of Jun 30, 2026.
Sources:13G/A by FMR (Oct 7, 2026) ↗13G by James B. Tananbaum (Feb 11, 2026) ↗13G by BlackRock Portfolio Management (Apr 29, 2026) ↗13G by Perlmutter Roger M (May 13, 2026) ↗13G by Innovation Endeavors III (May 15, 2026) ↗All of the company's proxy statements on EDGAR ↗
13F percentages divide the shares each institution reports by the shares outstanding on the cover of the company's latest report before the quarter end (May 1, 2026). Entities of the same group file separately and are not added up. We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.
Quarter flow (concentrated managers)
Change in managers (2 → 3): 1 opened · 0 exited = +1
Net flow in the quarter: +$495K (+38 K shares) · bought $495K and sold $0Shares concentrated managers added minus those they cut, valued at the 13F quarter-end implied price, not each trade's price. It is a different measure from the change in managers: the two can have opposite signs.
Concentrated managers holding it
- EcoR1 Capital$9.6M0.5%
- Baker Bros. Advisors$7.2M0.0%
- TCG Crossover ManagementNew$495K0.0%+0.0 pp
Up to 15, sorted by position value. The percentage is the weight in each manager's portfolio.
Largest holders of EIKN (all 13F filers)
- FMR5.0 MInvestment firm+1.2 M
- BlackRock4.3 MIndex manager+962 K
- Foresite Capital Management IV1.9 MPrivate equity or venture capital0
- Merck1.7 MOperating company0
- T. Rowe Price Investment Management1.6 MInvestment firm+373 K
- Foresite Capital Management V1.3 MPrivate equity or venture capital0
- Capital World Investors1.2 MInvestment firm+32 K
- Price T Rowe Associates1.0 MInvestment firm+29 K
- Vanguard Capital Management923 KIndex manager−47 K
- EcoR1 Capitalconcentrated733 KInvestment firm0
- Shares
- 5.0 M
- Change
- +1.2 M
See more
- Type
- Investment firm
- Value
- $65.2M
- Shares
- 4.3 M
- Change
- +962 K
See more
- Type
- Index manager
- Value
- $55.9M
- Shares
- 1.9 M
- Change
- 0
See more
- Type
- Private equity or venture capital
- Value
- $25.4M
- Merck
- Shares
- 1.7 M
- Change
- 0
See more
- Type
- Operating company
- Value
- $21.7M
- Shares
- 1.6 M
- Change
- +373 K
See more
- Type
- Investment firm
- Value
- $20.8M
- Shares
- 1.3 M
- Change
- 0
See more
- Type
- Private equity or venture capital
- Value
- $17.2M
- Shares
- 1.2 M
- Change
- +32 K
See more
- Type
- Investment firm
- Value
- $15.3M
- Shares
- 1.0 M
- Change
- +29 K
See more
- Type
- Investment firm
- Value
- $13.1M
- Shares
- 923 K
- Change
- −47 K
See more
- Type
- Index manager
- Value
- $12.0M
- EcoR1 Capitalconcentrated
- Shares
- 733 K
- Change
- 0
See more
- Type
- Investment firm
- Value
- $9.6M
The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.
Held by institutions (13F)
Institutions (13F): 48.9% of the shares · top 10: 36.3% · in index firms: 25.8% of the institutional total
Shares reported by the 77 13F filers as of Jun 30, 2026, divided by the shares outstanding on the cover of the company's latest report (May 1, 2026). It is not all institutional ownership: only managers above $100M file a 13F, and it excludes short positions. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. We only publish it where the figure is credible: not for ADRs, companies with more than one share class or stale shares-outstanding data.
Fundamentals
Balance sheet only, for now. EIKN has not yet filed its first annual report (10-K) with the SEC, so there are no 12-month figures (revenue, margins, earnings and cash flow). We show the balance sheet from its latest filing; once the 12-month figures are available, this section fills in automatically.
- Cash and equivalents
- $143M
- Investments
- $389M
- Shareholders' equity
- $467M
Balance sheet figures the company filed with the SEC (10-Q or 10-K), in dollars. Net debt = total debt − cash − investments; when negative, the company has more cash than debt (net cash). How each figure is calculated
Insiders (Form 4)
10% owners who bought (6 m): 1 · $1.0M
Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.
Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →
Above 5% (13D/13G)
Disclosed stakes, with their amendments. A filing is not always a purchase: there are also reductions and changes of filing entity.
This list may be incomplete: we hold 13D and 13G filings made since Dec 23, 2024. A holder above 5% that has not filed anything since then is not shown here.
Above 5% over time (13D/13G)
Each holder with its filings in order. History since December 2024.
Flagged material events (8-K)
Change in directors or officers (Item 5.02)
Change in directors or officers (Item 5.02)
Alert items the company itself flagged in its 8-K filings with the SEC, most serious first. It is the form's label, with no interpretation from us: Item 5.02 covers routine appointments as well as a chief executive's departure; open the filing. The quoted headline is the original press release's.
All material events (8-K)
Earnings, agreements, financing, management changes and announcements from the last year, with a filter by type and a link to each filing.
Other Health Care stocks in managers' portfolios
Same sector and a similar number of concentrated managers holding them. It is a list to keep exploring, not a recommendation.
- Agios PharmaceuticalsAGIO · 4 managers
- DavitaDVA · 4 managers
- KardiganKARD · 4 managers
- MapLight TherapeuticsMPLT · 4 managers
- Anteris Technologies GlobalAVR · 5 managers
- Compass TherapeuticsCMPX · 5 managers